Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD-1473 in moderately-to-severely active ulcerative colitis
NCT02818686Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Oct 2016
- Primary completion
- Mar 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, randomised, double-blind trial of izencitinib in ulcerative colitis (UC) (4 arms), sponsored by Theravance Biopharma, Inc. Primary endpoints: Treatment-emergent Adverse Events, Moderate or Severe Treatment-emergent Adverse Events and 10 more. Started Oct 2016; status: completed.
02
Drugs
izencitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02818686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02818686.